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Jennifer Dreyfus, MBA, MBE provides
consulting focused on the intersection
of new technology, health care, and
managing risk. As a Fellow at the Presidential
Commission for the Study of Bioethical
Issues, she worked on the PRIVACY and
PROGRESS in Whole Genome Sequencing
Report. She is very interested in examining
how society will incorporate the growing field
of genetics. Her academic background in
business administration and bioethics offers a
unique perspective on this issue.
Ms. Dreyfus opened her presentation by
emphasizing the idea that next-generation
genome sequencing is a disruptive
technology. Although next-generation
sequencing plays a significant role in
cancer care, genomic testing is also used
in preconception, prenatal, childhood and
adult diagnostics, and treatment monitoring.
Dreyfus cites one study that predicts over
$15-25 billion in national expenditures will be
spent on genomics by 2021.

Dreyfus explained that this is a time of
transition; genomics is a moving target that
changes the way we think about genetics.
For example, we are no longer looking at one
gene and one disorder; we are looking at a
spectrum of mutations that can be identified.
There are numerous pathogenic descriptions
that require sorting out and interpretation.
Gene panels are used to identify a variety of
conditions and will have many ramifications
in the future.
The benefits of identifying disease and
appropriate, personalized treatment through
genomic medicine raise a number of
public policy concerns. Dreyfus identifies
actionability, coding, payment, provider
education, and re-interpretations as
significant policy challenges that warrant
discussion and analysis. For example, Dreyfus
states that coding is very important, but
code development cannot keep pace with
scientific advances. Related to this, payers
want to pay for something that is known and
evidence-based. What are the appropriate
evidentiary requirements? What is a fair
method for rate setting? These are some of
the questions that Dreyfus poses.

Dreyfus summarized her presentation with
an overview of ethical concerns. She raised
the issue of whether or not there is truly
such a thing as anonymous DNA anymore
and whether or not privacy is guaranteed.
She stressed that genetics is about more
than an individual, and that it is also about
a family and a community. Are we treating
the individual or family and how does this
relate to privacy? She also discussed ACMG’s
latest guidance on incidental findings and
implications for reporting and paying.
Prenatal and newborn concerns related to
genetic testing often bring ethical concerns
to the forefront. In prenatal care there is
often tension between a technology that
gives health care information and a restrictive
environment that does not view reproductive
options as part of health care. Though
screening for adult-onset disorders is not
typical, there can be value for screening
newborns when an early intervention
is possible.
To listen to Forum podcasts and access
presentations visit:
JDC.Jefferson.edu/hpforum
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